Viva Biotech Holdings
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Viva Biotech Holdings (VBIZF) is a leading provider of drug discovery and development services to the biotechnology and pharmaceutical industries. The company offers an integrated suite of research solutions, including structure-based drug discovery, medicinal chemistry, assay development and screening, process development, and kilogram-scale manufacturing; it operates specialized CRO (contract research organization) and CMO (contract manufacturing organization) platforms through brands such as Viva Biotech, LakePharma (following its acquisition), and ChemPartner. Headquartered in Shanghai, China, and founded in 2003, Viva Biotech maintains global operations across Asia, North America, and Europe, serving clients ranging from startups to multinational pharmaceutical firms with target markets in oncology, immunology, and central nervous system disorders. In recent developments, Viva Biotech expanded its capabilities through the 2023 acquisition of LakePharma, a U.S.-based biologics CRO, enhancing its end-to-end biologics services including antibody discovery and cell line development. The company also secured strategic partnerships, such as a collaboration with WuXi AppTec in 2024 for advanced AI-driven drug design platforms, and completed a significant funding round in late 2024 to support capacity expansion in its Shanghai and California facilities. These moves reflect a major strategic shift toward integrated biopharma services, including new launches in PROTAC (proteolysis targeting chimera) technology and continuous manufacturing processes.
Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up
Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA
Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth
Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection
Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D
Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms
Vita Biotech Retains CBIH Services for Clinical Studies
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
Viva Biotech Secures Approximately US$ 210 Million Funding
Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability
Viva Biotech's Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing
Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse